Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients

IntroductionCollagenous colitis (CC) is an inflammatory bowel disease, which usually responds to budesonide treatment. Our aim was to study the immunological background of the disease.MethodsAnalyses of peripheral and mucosal MAIT (mucosa associated invariant T cells) and NK (natural killer) cells w...

Full description

Bibliographic Details
Main Authors: Niki Daferera, Sofia Nyström, Henrik Hjortswang, Simone Ignatova, Maria C. Jenmalm, Magnus Ström, Andreas Münch
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.981740/full
_version_ 1828116923730100224
author Niki Daferera
Sofia Nyström
Sofia Nyström
Henrik Hjortswang
Simone Ignatova
Maria C. Jenmalm
Magnus Ström
Andreas Münch
author_facet Niki Daferera
Sofia Nyström
Sofia Nyström
Henrik Hjortswang
Simone Ignatova
Maria C. Jenmalm
Magnus Ström
Andreas Münch
author_sort Niki Daferera
collection DOAJ
description IntroductionCollagenous colitis (CC) is an inflammatory bowel disease, which usually responds to budesonide treatment. Our aim was to study the immunological background of the disease.MethodsAnalyses of peripheral and mucosal MAIT (mucosa associated invariant T cells) and NK (natural killer) cells were performed with flow cytometry. Numbers of mucosal cells were calculated using immunohistochemistry. We studied the same patients with active untreated CC (au-CC) and again while in remission on budesonide treatment. Budesonide refractory patients and healthy controls were also included. The memory marker CD45R0 and activation marker CD154 and CD69 were used to further study the cells. Finally B cells, CD4+ and CD8+ T cells were also analysed.ResultsThe percentages of circulating CD56dimCD16+ NK cells as well as MAIT cells (CD3+TCRVa7.2+CD161+) were decreased in au-CC compared to healthy controls. This difference was not seen in the mucosa; where we instead found increased numbers of mucosal CD4+ T cells and CD8+ T cells in au-CC. Mucosal immune cell numbers were not affected by budesonide treatment. In refractory CC we found increased mucosal numbers of MAIT cells, CD4+ and CD8+ T cells compared to au-CC.DiscussionPatients with active collagenous colitis have lower percentages of circulating MAIT and NK cells. However, there was no change of these cells in the colonic mucosa. Most mucosal cell populations were increased in budesonide refractory as compared to au-CC patients, particularly the number of MAIT cells. This may indicate that T cell targeting therapy could be an alternative in budesonide refractory CC.
first_indexed 2024-04-11T13:06:02Z
format Article
id doaj.art-66f454ea566c4c69a5bad0b0bbed974c
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-11T13:06:02Z
publishDate 2022-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-66f454ea566c4c69a5bad0b0bbed974c2022-12-22T04:22:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.981740981740Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patientsNiki Daferera0Sofia Nyström1Sofia Nyström2Henrik Hjortswang3Simone Ignatova4Maria C. Jenmalm5Magnus Ström6Andreas Münch7Department of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, SwedenDepartment of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, SwedenDepartment of Clinical Immunology and Transfusion Medicine, Linköping University, Linköping, SwedenDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, SwedenDepartment of Pathology, Linköping University, Linköping, SwedenDepartment of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, SwedenDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, SwedenDepartment of Gastroenterology, Faculty of Health Sciences, Linköping University, Linköping, SwedenIntroductionCollagenous colitis (CC) is an inflammatory bowel disease, which usually responds to budesonide treatment. Our aim was to study the immunological background of the disease.MethodsAnalyses of peripheral and mucosal MAIT (mucosa associated invariant T cells) and NK (natural killer) cells were performed with flow cytometry. Numbers of mucosal cells were calculated using immunohistochemistry. We studied the same patients with active untreated CC (au-CC) and again while in remission on budesonide treatment. Budesonide refractory patients and healthy controls were also included. The memory marker CD45R0 and activation marker CD154 and CD69 were used to further study the cells. Finally B cells, CD4+ and CD8+ T cells were also analysed.ResultsThe percentages of circulating CD56dimCD16+ NK cells as well as MAIT cells (CD3+TCRVa7.2+CD161+) were decreased in au-CC compared to healthy controls. This difference was not seen in the mucosa; where we instead found increased numbers of mucosal CD4+ T cells and CD8+ T cells in au-CC. Mucosal immune cell numbers were not affected by budesonide treatment. In refractory CC we found increased mucosal numbers of MAIT cells, CD4+ and CD8+ T cells compared to au-CC.DiscussionPatients with active collagenous colitis have lower percentages of circulating MAIT and NK cells. However, there was no change of these cells in the colonic mucosa. Most mucosal cell populations were increased in budesonide refractory as compared to au-CC patients, particularly the number of MAIT cells. This may indicate that T cell targeting therapy could be an alternative in budesonide refractory CC.https://www.frontiersin.org/articles/10.3389/fimmu.2022.981740/fullcollagenous colitisbudesonidemicroscopic colitis (MC)MAIT cellnatural killar cells
spellingShingle Niki Daferera
Sofia Nyström
Sofia Nyström
Henrik Hjortswang
Simone Ignatova
Maria C. Jenmalm
Magnus Ström
Andreas Münch
Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients
Frontiers in Immunology
collagenous colitis
budesonide
microscopic colitis (MC)
MAIT cell
natural killar cells
title Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients
title_full Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients
title_fullStr Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients
title_full_unstemmed Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients
title_short Mucosa associated invariant T and natural killer cells in active and budesonide treated collagenous colitis patients
title_sort mucosa associated invariant t and natural killer cells in active and budesonide treated collagenous colitis patients
topic collagenous colitis
budesonide
microscopic colitis (MC)
MAIT cell
natural killar cells
url https://www.frontiersin.org/articles/10.3389/fimmu.2022.981740/full
work_keys_str_mv AT nikidaferera mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT sofianystrom mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT sofianystrom mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT henrikhjortswang mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT simoneignatova mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT mariacjenmalm mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT magnusstrom mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients
AT andreasmunch mucosaassociatedinvarianttandnaturalkillercellsinactiveandbudesonidetreatedcollagenouscolitispatients